PMC:7105881 / 33193-33440
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1085 | 0-8 | Species | denotes | SARS-CoV | Tax:694009 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T177 | 0-8 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T178 | 170-174 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T440 | 132-133 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32265848-15474494-36511136 | 196-200 | 15474494 | denotes | 2004 |
32265848-23252385-36511138 | 223-227 | 23252385 | denotes | 2012 |
32265848-23977435-36511139 | 241-245 | 23977435 | denotes | 2013 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T198 | 0-247 | Sentence | denotes | SARS-CoV RBD contains multiple conformation-dependent epitopes capable of eliciting high-titer neutralizing antibodies; thus, it is a major target for the development of SARS vaccines (He et al., 2004, 2005a; Jiang et al., 2012; Zhu et al., 2013). |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T556 | 0-8 | SP_10 | denotes | SARS-CoV |
T557 | 54-62 | BV_9 | denotes | epitopes |
T558 | 108-118 | GO:0042571 | denotes | antibodies |
T559 | 170-174 | SP_10 | denotes | SARS |
T54867 | 0-8 | SP_10 | denotes | SARS-CoV |
T62823 | 54-62 | BV_9 | denotes | epitopes |
T18461 | 108-118 | GO:0042571 | denotes | antibodies |
T90326 | 170-174 | SP_10 | denotes | SARS |